日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

A plasma-based DNA test for quantification of disease burden in acute myeloid leukemia patients undergoing bone marrow transplantation

一种基于血浆的DNA检测方法,用于量化接受骨髓移植的急性髓系白血病患者的疾病负荷

Wang, Yuxuan; Xie, Jiajun; Pasca, Sergiu; Popoli, Maria; Ptak, Janine; Dobbyn, Lisa; Silliman, Natalie; Paul, Suman; Jones, Richard J; Levis, Mark J; Curtis, Samuel D; Douville, Christopher; Shams, Cynthia; Guo, Matthew Z; Mo, Shirley; Gocke, Christopher D; Malek, Sami N; Bollard, Catherine M; Bettegowda, Chetan; Kinzler, Kenneth W; Vogelstein, Bert; Papadopoulos, Nickolas; Gondek, Lukasz P

Erratum to: "Impact of hematopoietic cell transplantation and quizartinib in newly diagnosed patients with acute myeloid leukemia and FMS-like tyrosine kinase 3-internal tandem duplications in the QuANTUM-First trial"

更正:“在QuANTUM-First试验中,造血细胞移植和quizartinib对新诊断的伴有FMS样酪氨酸激酶3内部串联重复的急性髓系白血病患者的影响”

Schlenk, Richard F; Montesinos, Pau; Kim, Hee-Je; Romero-Aguilar, Antonio; Vrhovac, Radovan; Patkowska, Elżbieta; Žák, Pavel; Wang, Po-Nan; Hanyok, James; Liu, Li; Kamel, Yasser Mostafa; Imadalou, Karima; Lesegretain, Arnaud; Cortes, Jorge; Sekeres, Mikkael A; Dombret, Hervé; Amadori, Sergio; Wang, Jianxiang; Perl, Alexander E; Levis, Mark J; Erba, Harry P

C-C motif chemokine receptor-like 2 promotes the interferon-γ signaling response in myeloid neoplasms with erythroid differentiation and mutated TP53.

CC 基序趋化因子受体样 2 促进具有红系分化和 TP53 突变的髓系肿瘤中的干扰素-γ 信号反应。

Naji Nour Sabiha, Pasca Sergiu, Chatzilygeroudi Theodora, Toledano-Sanz Pablo, Rimando Joseph, An Yuju, Hemani Yashvi, Perkins Brandy, Zeng Xinghan, Talbot Conover Jr, Paun Bogdan, Abdulmalik Abdulmuez, Lossos Chen, Boronina Tatianna R, Sinanidis Ilias, Tsakiroglou Panagiotis, Fernandes Priyanka, Esteb Christopher, Ambinder Alexander J, Cole Robert N, Xian Rena, Gojo Ivana, Paul Suman, Levis Mark J, DeZern Amy E, Luznik Leo, Karanika Styliani, Resar Linda S, Jones Richard J, Bunz Frederick, Gondek Lukasz, Arvanitis Marios, Karantanos Theodoros

Conditioning, MRD, and NPM1 comutation in the MORPHO trial

MORPHO试验中的条件反射、MRD和NPM1突变

Levis, Mark J; Hamadani, Mehdi; Chen, Yi-Bin

FLT3-ITD measurable residual disease from the QuANTUM-First trial

Quantum-First试验中FLT3-ITD可测量残留病灶

Levis, Mark J; Erba, Harry P; Montesinos, Pau; Kim, Hee-Je; Vrhovac, Radovan; Patkowska, Elżbieta; Žák, Pavel; Wang, Po-Nan; Connolly Rohrbach, Jaime E; Chang, Ken C N; Liu, Li; Mostafa Kamel, Yasser; Imadalou, Karima; Lesegretain, Arnaud; Cortes, Jorge; Sekeres, Mikkael A; Dombret, Hervé; Amadori, Sergio; Wang, Jianxiang; Schlenk, Richard F; Perl, Alexander E

Measurable residual disease and posttransplantation gilteritinib maintenance for patients with FLT3-ITD-mutated AML

对于FLT3-ITD突变型急性髓系白血病患者,可测量的残留病灶和移植后吉瑞替尼维持治疗。

Levis, Mark J; Hamadani, Mehdi; Logan, Brent R; Jones, Richard J; Singh, Anurag K; Litzow, Mark R; Wingard, John R; Papadopoulos, Esperanza B; Perl, Alexander E; Soiffer, Robert J; Ustun, Celalettin; Oshima, Masumi Ueda; Uy, Geoffrey L; Waller, Edmund K; Vasu, Sumithira; Solh, Melhem; Mishra, Asmita; Muffly, Lori S; Kim, Hee-Je; Stelljes, Matthias; Najima, Yuho; Onozawa, Masahiro; Thomson, Kirsty; Nagler, Arnon; Wei, Andrew H; Marcucci, Guido; Chen, Caroline; Hasabou, Nahla; Rosales, Matt; Hill, Jason; Gill, Stanley C; Nuthethi, Rishita; King, Denise; Mendizabal, Adam; Devine, Steven M; Horowitz, Mary M; Chen, Yi-Bin

Outcome of adult acute myeloid leukemia patients with extramedullary disease and treatment with venetoclax/ hypomethylating agents

成人急性髓系白血病伴髓外病变患者接受维奈托克/去甲基化药物治疗的预后

Kayser, Sabine; Sanber, Khaled; Marconi, Giovanni; Mattei, Agnese; Luskin, Marlise R; Kelkar, Amar; Cerrano, Marco; Kristensen, Daniel Tuyet; Roug, Anne Stidsholt; Sartor, Chiara; Giglio, Fabio; Riva, Marta; Rizzo, Lorenzo; Saraceni, Francesco; Guerzoni, Selene; Lessi, Federica; Borlenghi, Erika; Levis, Mark J; Schlenk, Richard F; Jain, Tania; Papayannidis, Cristina

Impact of hematopoietic cell transplantation and quizartinib in newly diagnosed patients with acute myeloid leukemia and FMS-like tyrosine kinase 3-internal tandem duplications in the QuANTUM-First trial

在QuANTUM-First试验中,造血干细胞移植和quizartinib对新诊断的伴有FMS样酪氨酸激酶3内部串联重复的急性髓系白血病患者的影响

Schlenk, Richard F; Montesinos, Pau; Kim, Hee-Je; Romero-Aguilar, Antonio; Vrhovac, Radovan; Patkowska, Elżbieta; Žak, Pavel; Wang, Po-Nan; Hanyok, James; Liu, Li; Kamel, Yasser Mostafa; Imadalou, Karima; Lesegretain, Arnaud; Cortes, Jorge; Sekeres, Mikkael A; Dombret, Herve; Amadori, Sergio; Wang, Jianxiang; Perl, Alexander E; Levis, Mark J; Erba, Harry P

Improved outcomes of acute lymphoblastic leukemia after allogeneic blood or marrow transplantation with highdose post-transplantation cyclophosphamide in the era of more effective pre-transplant therapy

在移植前治疗效果日益显著的时代,采用高剂量移植后环磷酰胺治疗异基因造血干细胞移植或骨髓移植可改善急性淋巴细胞白血病患者的预后。

Webster, Jonathan A; Reed, Madison; Tsai, Hua-Ling; Imus, Philip H; Smith, Douglas B; Ambinder, Alexander J; Levis, Mark J; DeZern, Amy E; Prince, Gabrielle T; Jain, Tania; Bolaños-Meade, Javier; Gondek, Lukasz P; Ghiaur, Gabriel; Dalton, William Brian; Karantanos, Theodoros; Paul, Suman; Fuchs, Ephraim J; Sterling, Cole; Swinnen, Lode J; Wagner-Johnston, Nina; Ambinder, Richard F; Gocke, Christian B; Ali, Syed Abbas; Huff, Carol Ann; Luznik, Leo; Varadhan, Ravi; Jones, Richard J; Gojo, Ivana

Impact of transplant conditioning, NPM1 mutations, and measurable residual disease in FLT3-ITD acute myeloid leukemia

移植预处理、NPM1突变和可测量残留病灶对FLT3-ITD急性髓系白血病的影响

Levis, Mark J; Hamadani, Mehdi; Logan, Brent R; Jones, Richard J; Singh, Anurag K; Litzow, Mark R; Wingard, John R; Papadopoulos, Esperanza B; Perl, Alexander E; Soiffer, Robert J; Ustun, Celalettin; Oshima, Masumi Ueda; Uy, Geoffrey L; Waller, Edmund K; Vasu, Sumithira; Solh, Melhem; Mishra, Asmita; Muffly, Lori S; Kim, Hee-Je; Stelljes, Matthias; Najima, Yuho; Onozawa, Masahiro; Thomson, Kirsty; Chen, Caroline; Hasabou, Nahla; Rosales, Matt; Hill, Jason E; Gill, Stanley C; Nuthethi, Rishita; King, Denise; Mendizabal, Adam; Devine, Steven M; Horowitz, Mary M; Chen, Yi-Bin